BIOMARIN PHARMACEUTICAL INC 8-K/A

What Happened BioMarin Pharmaceutical Inc. filed a Current Report on Form 8-K/A on July 13, 2026 to provide financial statements and exhibits (Item 9.01, .01(a) and .01(b)) that were omitted from an earlier 8-K in reliance on Form 8-K instructions. The amendment includes pro forma financial information related to BioMarin’s acquisition of Amicus. The company states the pro forma data is presented for informational purposes only and is not necessarily indicative of the combined financial position or results had the acquisition occurred on the dates shown, nor of future results.

Key Details

• Filing type: Form 8-K/A (amendment) filed 2026-07-13 to add Item 9.01 disclosures (.01(a) and .01(b)).
• Subject: Pro forma financial information tied to BioMarin’s acquisition of Amicus.
• Company disclosure: Pro forma figures are informational and “not necessarily indicative” of what combined results would have been or will be.
• The financial information was originally excluded from the prior 8-K in reliance on the instructions to those items.

Why It Matters This amendment provides investors with the previously omitted financial statements and pro forma financials tied to the Amicus acquisition, giving additional data to evaluate the transaction. However, BioMarin explicitly warns the pro forma numbers are for informational purposes only and should not be treated as definitive evidence of combined past performance or future results; investors should review the full filings and any future disclosures for a complete picture.